Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECI830 With or Without Ribociclib and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer and Advanced Solid Tumors
CTR20260185Phase 2Active
- Sponsor
- Novartis
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ECI830 in breast cancer, Nonhematologic neoplasms, sponsored by Novartis. Started Apr 2026; status: active.
02
Drugs
ECI830
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20260185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260185.